Grace Therapeutics (NASDAQ: GRCE) — research report

Built from primary sources (SEC filings, official company press releases, ClinicalTrials.gov, and a peer-reviewed protocol reference). Informational only; not investment advice.

Executive summary

Grace Therapeutics has disclosed that it submitted an NDA for GTx-104 (intravenous nimodipine) on June 25, 2025, and that the FDA accepted the application for review with a PDUFA target date of April 23, 2026. Company Company

BULLISH

FDA acceptance for review plus a stated PDUFA target date (April 23, 2026) creates a defined regulatory timeline anchor. Company

NEUTRAL

STRIVE-ON is described as a Phase 3 safety study supporting a 505(b)(2) pathway; acceptance and timelines do not imply approval outcome. CT

BEARISH

Company disclosures describe limited runway and reliance on cash planning and potential warrant proceeds. Company

Quick data (primary-source anchored)

Confirmed PDUFA target date

April 23, 2026 Company

Cash & cash equivalents (Sep 30, 2025)

$16.9M Company

Estimated cash & cash equivalents (Oct 31, 2025)

~$20.0M Company

Company snapshot

Corporate identifier (SEC proxy materials)

Address: 103 Carnegie Center, Suite 300, Princeton, NJ 08540 SEC

Pipeline

Pipeline items below reflect company disclosures and primary registries where available.

Program	Indication	Stage / status (as disclosed)	Primary sources
GTx-104	Aneurysmal subarachnoid hemorrhage (aSAH)	NDA submitted; FDA accepted for review; PDUFA April 23, 2026	Company Company CT
GTx-102	Ataxia-telangiectasia	Deprioritized; potential out-licensing / sale (company disclosure)	Company
GTx-101	Postherpetic neuralgia (PHN)	Deprioritized; potential out-licensing / sale (company disclosure)	Company

Lead program: GTx-104

Study registry

STRIVE-ON: NCT05995405 CT

Company-disclosed trial summary (STRIVE-ON)

The NDA submission release describes a randomized open-label comparison (GTx-104 vs oral nimodipine; 50 vs 52) and states the trial met its primary endpoint, providing comparative figures for hypotension and dose intensity. Company

Metric (as disclosed)	GTx-104	Oral nimodipine	Source
At least one incidence of clinically significant hypotension	28%	35%	Company
Relative dose intensity (RDI) of 95% or higher	54%	8%	Company
Deaths (trial arms)	8	4 (plus 1 unknown survival status)	Company

Peer-reviewed protocol reference

A peer-reviewed protocol description references STRIVE-ON and describes it as designed to support a 505(b)(2) pathway for FDA approval. PubMed

BULLISH

Multiple trial endpoints are described as favorable in company communications, with a clear NDA submission milestone. Company

NEUTRAL

Trial interpretation remains contingent on FDA review, label language, and full CMC assessment.

BEARISH

Any FDA manufacturing/CMC concerns can alter timelines and commercial readiness, independent of clinical narratives.

Regulatory status and catalysts

NDA timeline (company disclosures)

NDA submitted: June 25, 2025 Company
FDA acceptance for review; PDUFA target date: April 23, 2026 Company

Date / window	Status	Event	Program	Source
April 23, 2026	CONFIRMED	FDA PDUFA target date for NDA review	GTx-104	Company

Financial snapshot and runway

Company-disclosed cash and runway language

Cash & cash equivalents: $16.9M (Sep 30, 2025) Company
Estimated cash & cash equivalents: ~$20.0M (Oct 31, 2025) after ~$4.0M gross proceeds from warrant exercises in October 2025 Company
Runway framing: company states runway through at least the next twelve months; could extend into Q2 2027 if Feb 2025 warrants are exercised (company disclosure) Company

SEC filing cash reference (quarter ended June 30, 2025)

The Form 10-Q for the quarter ended June 30, 2025 reports cash and cash equivalents of 20,005 (expressed in thousands in the filing context). SEC

Risks

Non-exhaustive risk map (evidence anchored)

Regulatory: PDUFA is a timeline item, not an outcome; FDA action may include approval, label restrictions, or additional requirements.
CMC/manufacturing: parenteral products often face manufacturing and inspection scrutiny that can affect timelines.
Funding and dilution: company disclosures describe runway limitations and potential reliance on warrant proceeds. Company
Portfolio concentration: deprioritization of non-core programs increases near-term dependence on GTx-104. Company

Full risk factors should be reviewed directly in the company’s periodic reports. SEC 10-K SEC 10-Q

Sentiment

High-level read of the public narrative

Across public trading communities, the discussion around GRCE is heavily event-driven. The dominant narrative is the regulatory timeline for GTx-104 (FDA acceptance + PDUFA date) and what that could mean for a micro-cap name. A second recurring narrative is financing: cash runway, warrant exercises, and dilution risk. A third theme is debate about the practical relevance of the STRIVE-ON summary metrics (hypotension, dose intensity, etc.).

Recurring themes seen in community discussion

PDUFA-first framing: many posts revolve around “countdown to PDUFA” and tracking company updates leading into April 2026.
Cash runway and dilution: frequent focus on cash levels, warrant exercises and “how long the company can operate” without new financing.
Trial summary debate: discussion often references the company’s STRIVE-ON summary numbers and argues about real-world relevance (safety, dosing practicalities, and label expectations).
Microcap volatility: frequent “price talk” typical of small caps (short-term spikes, catalysts, and momentum), with varying quality of reasoning.
Conference/abstract visibility: occasional bursts of attention when an abstract or meeting mention appears in news-style feeds.

Representative public sources (for context)

Reddit — “what’s next” discussion: Reddit
Reddit — “can go higher” style thesis post: Reddit
Reddit — warrants / SECWatch summary: Reddit
Reddit — biotech_stocks community summary post: Reddit
Reddit — community hub (GRCE-focused): Reddit
News-style community post (abstract/meeting mention): Reddit
X (Twitter) search feed: X
Alternative community forum (moomoo): Forum

Sources

Company press releases

NDA submission (Jun 25, 2025) Company
FDA acceptance for review + PDUFA (Aug 27, 2025) Company
Q2 2026 results / business update (Nov 13, 2025) Company
Warrant exercises update (Oct 23, 2025) Company

SEC filings

Form 10-Q (quarter ended June 30, 2025) SEC
Form 10-K (fiscal year ended March 31, 2025) SEC
DEF 14A (proxy materials) SEC

ClinicalTrials.gov

NCT05995405 (STRIVE-ON) CT

Peer-reviewed protocol reference

STRIVE-ON protocol reference (PubMed Central) PubMed

Tools & Partners

Finviz
ChartsWatcher — ChartsWatcher is a real-time, next-generation scanner for the US stock market.
Seeking Alpha
Stocktwits
Medved Trader (no referral link)
Merlintrader trading Blog

Affiliate note: some links above may be affiliate/referral links. If used, they may support the project at no additional cost.

Support the project

If these reports are useful and keeping the site free matters, support via PayPal donation.

Donate via PayPal

Disclaimers

This report is provided for informational and educational purposes only. It is not investment advice, not a solicitation, and not a recommendation to buy or sell any security. The content reflects personal interpretation of public documents and may contain errors; the linked primary sources remain the definitive references.

This report is not prepared by a registered investment adviser, broker-dealer, or financial analyst. Biotech and small-cap stocks can be highly volatile and can result in significant losses.

Legal resources: Disclaimer Terms & Privacy

Authors: Merlintrader and Jane.

In every report I share things as I personally interpret them, based on the raw data from official filings, company communications, and primary verified sources where available. I do not write to promote enthusiasm or pessimism; these are simply my own views as a trader, not as a professional analyst. Market sentiment can shift quickly. Official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If something looks off, it can be corrected in a future revision. This is not professional work; it is an effort to be transparent, data-driven, and consistent.

Biotech Catalyst Calendar

Central page for upcoming biotech catalysts and dates.

Open Biotech Catalyst Calendar

Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Authors: Merlintrader, Jane and Gemini

Author's note (English)

In every report I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this report as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

AI usage disclosure (English)

This report has been prepared using a human + AI workflow. Drafting, editing and data organisation are supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Legal disclaimer (English) – please read carefully

This report is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in this document should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in this report, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this document is not investment advice and should not be used as such.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana che inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicated here sotto.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Tools and research platforms used in this report

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

Some of the links above are affiliate links. If you decide to subscribe or purchase through them, it may generate a small commission for Merlintrader at no extra cost to you. This helps keep the site online and the reports freely accessible. You are under no obligation to use these links; always choose the solution that best fits your needs and your own evaluation.

Full legal information, risk warnings and terms of use (in both Italian and English) are available on the official Merlintrader legal pages:

Italian version: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

The same pages also include the corresponding English text or an English equivalent of the main legal notices, so that international readers can access the core risk disclosures and terms of use.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

Authors: Merlintrader, Jane and Gemini

Nota dell'autore (Italiano)

In ogni report condivido ciò che vedo e come lo interpreto personalmente, partendo dai dati grezzi di documenti ufficiali, comunicazioni delle società, trascrizioni delle call e altre fonti primarie quando disponibili. Alcune parti del lavoro di ricerca e di impaginazione sono supportate da assistenti IA (Jane e Gemini), che mi aiutano a organizzare i dati, verificare i dettagli e migliorare grafici o elementi visivi. Le valutazioni finali, le opinioni e le conclusioni restano comunque esclusivamente mie, da trader come te, non da consulente finanziario abilitato o analista iscritto ad albi professionali. Il sentiment di mercato può cambiare molto rapidamente, mentre i documenti ufficiali e i numeri restano quelli che sono. È anche possibile che commetta errori: raccogliere e confrontare tempistiche FDA, dati clinici, filing e aggiornamenti societari è un lavoro complesso, quindi qualche imprecisione può sfuggire. Se noti qualcosa che non ti torna, segnalamelo e lo correggerò. Non considerare questo report come consulenza personalizzata, ma come materiale informativo da confrontare con le tue ricerche e con il parere di professionisti qualificati.

Informativa sull'uso di IA generativa (Italiano)

Questo report è stato redatto utilizzando un flusso di lavoro combinato umano + IA. La stesura, la revisione e l'organizzazione dei dati sono supportate da strumenti di intelligenza artificiale generativa, ad esempio modelli linguistici di grandi dimensioni forniti da terze parti, sulla base di istruzioni e controlli definiti dall'autore. Le fonti utilizzate sono pubbliche e la selezione finale delle informazioni, le verifiche, le opinioni e le conclusioni restano sotto la responsabilità esclusiva dell'autore.

Disclaimer legale (Italiano) – leggere con attenzione

Questo report ha finalità esclusivamente informative e didattiche. Non costituisce in alcun modo consulenza in materia di investimenti, ricerca in materia di investimenti in senso regolamentare, gestione di portafogli, né raccomandazione personalizzata o generica ad acquistare, vendere o detenere strumenti finanziari. L'autore non è un consulente finanziario abilitato all'esercizio della professione, non è un promotore finanziario, non è un analista iscritto ad albi professionali e non svolge servizi di investimento ai sensi della normativa vigente.

Qualsiasi riferimento a scenari possibili, livelli di prezzo, probabilità o catalyst ha valore puramente illustrativo e riflette una valutazione personale e non professionale basata su informazioni pubbliche disponibili al momento della stesura. Nulla di quanto scritto rappresenta sollecitazione al pubblico risparmio, offerta al pubblico di prodotti finanziari o promessa di rendimento o di protezione del capitale. In particolare, i titoli biotech e healthcare possono essere estremamente volatili e speculativi, soprattutto in prossimità di eventi clinici o regolatori (PDUFA, letture di trial, ecc.).

L'autore può detenere, o aver detenuto, posizioni long o short su alcuni degli strumenti finanziari menzionati nel report e può aprire, chiudere o modificare tali posizioni senza preavviso. Questa possibile coincidenza di interessi può influenzare il taglio o l'attenzione dell'analisi. La presenza di eventuali posizioni personali non trasforma in alcun modo questo documento in consulenza finanziaria e non deve essere interpretata come tale.

Prima di assumere qualsiasi decisione di investimento o di trading, è indispensabile effettuare le proprie analisi e valutazioni e, se necessario, rivolgersi a un consulente finanziario indipendente e abilitato, in grado di considerare la tua situazione personale, gli obiettivi e la propensione al rischio. Le informazioni riportate possono contenere errori, omissioni o non essere aggiornate; né l'autore né Merlintrader possono essere ritenuti responsabili per eventuali perdite, dirette o indirette, derivanti dall'utilizzo di questo contenuto.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicate qui sotto.

Se trovi utili questi report e vuoi sostenere il progetto, puoi fare una donazione volontaria una tantum tramite PayPal o Buy Me a Coffee. È un aiuto concreto per coprire i costi di dati, strumenti e hosting, così i contenuti possono restare indipendenti e liberamente accessibili.

Strumenti e piattaforme di ricerca usati in questo report

Qui sotto trovi una selezione di strumenti e piattaforme che uso personalmente per seguire prezzi, catalyst, fondamentali e sentiment. I link sono forniti solo per trasparenza e comodità del lettore.

Finviz Elite – screener avanzato e piattaforma grafica, usato per heatmap, performance relative e contesto tecnico.
ChartsWatcher – scanner real-time di nuova generazione per il mercato azionario USA. Lo uso per monitorare momentum intraday, picchi di volume e alert cromatici sui pattern.
Stocktwits – flusso social focalizzato sui ticker, usato solo come indicatore di sentiment e attività, non come fonte di raccomandazioni di investimento.
Monica.im – assistente AI usato per report leggeri, drafting e ricerche veloci; utile per strutturare note e prime analisi insieme al lavoro di approfondimento pubblicato su Merlintrader.
Medved Trader – piattaforma professionale di trading e charting usata per esecuzione real-time, order-flow e analisi intraday dettagliata. Nessun affiliate link; è citata perché fa parte del workflow operativo reale.
Merlintrader trading Blog – la casa dei report focalizzati sul biotech, delle dashboard e degli articoli educativi che approfondiscono i temi menzionati in questo documento.

Alcuni dei link sopra indicati sono link affiliati. Se decidi di iscriverti o acquistare tramite uno di essi, Merlintrader potrebbe ricevere una piccola commissione senza costi aggiuntivi per te. Questo aiuta a mantenere il sito online e i report liberamente accessibili. Non hai alcun obbligo di usare questi link: scegli sempre la soluzione che ritieni più adatta alle tue esigenze e alla tua valutazione personale.

Le informazioni legali complete, le avvertenze sui rischi e le condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali di Merlintrader:

Versione italiana: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

Le stesse pagine includono anche il testo corrispondente in inglese o un equivalente inglese delle principali avvertenze legali, così anche i lettori internazionali possono consultare le informazioni essenziali su rischi e condizioni d'uso.

Biotech Catalyst Calendar

Per una visione più ampia e continuamente aggiornata dei prossimi catalyst biotech (date PDUFA, principali letture cliniche, eventi regolatori e conferenze chiave), puoi consultare il calendario dedicato su Merlintrader.

Apri il Biotech Catalyst Calendar